Topics
News
CME/CE
Editorial Advisory Board
Partnerships
One Size Dose Doesn't Fit All
San Francisco - Results from premarketing clinical trials indicate that the usual efalizumab (Raptiva) dosage for the treatment of psoriasis will involve ongoing therapy with 1 mg/kg in the vast majority of patients, but alternate dosing regimens for fine-tuning management may benefit certain subgroups of patients, Kim A. Papp, M.D., said at the annual meeting of the American Academy of Dermatology.
Related Videos
Related Content
Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York
September 24th 2023
Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York
September 24th 2023
